<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03004287</url>
  </required_header>
  <id_info>
    <org_study_id>206241</org_study_id>
    <nct_id>NCT03004287</nct_id>
  </id_info>
  <brief_title>2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy</brief_title>
  <official_title>2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether adding one of the newest multiple myeloma therapies,&#xD;
      daratumumab, into the Total Therapy approach helps patients live longer with fewer side&#xD;
      effects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Past studies conducted at the Myeloma Institute and at other institutions have shown that&#xD;
      many patients with high-risk disease (as determined by gene array studies - studies that look&#xD;
      at specific genes using special equipment) tend to have shorter remissions (disappearance of&#xD;
      signs and symptoms of myeloma) and do not survive as long as participants with low-risk&#xD;
      myeloma. The Total Therapy approach to treatment carried out at the Myeloma Institute where&#xD;
      multiple chemotherapy agents are given as induction followed by a stem cell transplant,&#xD;
      post-transplant consolidation, and maintenance therapy has proven to be the best available&#xD;
      treatment strategy. However, the availability of new treatments that work in different ways&#xD;
      offers the possibility of improving the effectiveness of Total Therapy treatment while&#xD;
      potentially reducing the number of side effects patients' experience. Daratumumab is a human&#xD;
      monoclonal antibody or protein drug. It recognizes a specific protein, CD38, which is found&#xD;
      at high levels on multiple myeloma cells. An antibody is something that finds and kills&#xD;
      foreign objects in your body, in this case, myeloma cells. The other drugs that will be used&#xD;
      in the study treatment regimen include carfilzomib or bortezomib, thalidomide, lenalidomide,&#xD;
      dexamethasone, cisplatin, adriamycin, cyclophosphamide, etoposide, lenalidomide and&#xD;
      dexamethasone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the progression-free survival in patients with high risk multiple myeloma</measure>
    <time_frame>48 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Study Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).&#xD;
Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.&#xD;
Immunological Consolidation 1: Daratumumab.&#xD;
Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).&#xD;
ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.&#xD;
Immunological Consolidation 2: Daratumumab.&#xD;
Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.&#xD;
Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Kyprolis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Given by mouth at bedtime: days 1-4 of Induction</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Baycadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Darzalex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given by vein: days 1-4 (continuous infusion) of Induction</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>Given by vein: days 1-4 (continuous infusion) of Induction</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given by vein: days 1-4 (continuous infusion) of Induction</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given by vein: days 1-4 (continuous infusion) of Induction</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Eposin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given by vein: days -4 - -1 of Transplant(s)</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ASCT</intervention_name>
    <description>day 0 of Transplant(s)</description>
    <arm_group_label>Study Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician</description>
    <arm_group_label>Study Treatment</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have newly diagnosed active Multiple Myeloma (MM) requiring treatment.&#xD;
             Patients with a previous history of smoldering myeloma will be eligible if there is&#xD;
             evidence of progressive disease requiring chemotherapy.&#xD;
&#xD;
          -  Patients must be either untreated or have not received more than four cycles of&#xD;
             systemic MM therapy (e.g. Revlimid Dexamethasone (RD), Bortezomib Revlimid&#xD;
             Dexamethasone (VRD). Prior bisphosphonates and localized radiation are allowed.&#xD;
&#xD;
          -  Participants must have high-risk disease, as defined by at least one of the following:&#xD;
&#xD;
          -  Myeloma Prognostic Risk Signature (MyPRS) risk score ≥ 50.4&#xD;
&#xD;
          -  Lactate Dehydrogenase (LDH) ≥ 360 U/L (Rule out hemolysis and infection; contact PI if&#xD;
             any doubt.)&#xD;
&#xD;
          -  Diagnosis of primary plasma cell leukemia.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2, unless solely due to symptoms of&#xD;
             MM-related bone disease.&#xD;
&#xD;
          -  Patients must have a platelet count ≥ 50,000/μL, unless lower levels are explained by&#xD;
             extensive bone marrow plasmacytosis.&#xD;
&#xD;
          -  Patients must be at least 18 years of age and not older than 75 years of age at the&#xD;
             time of registration.&#xD;
&#xD;
          -  Participants must have a baseline serum creatinine level &lt; 3 mg/dL and baseline&#xD;
             Alanine Aminotransferase (ALT) &lt; 3x Upper Limit of Normal (ULN).&#xD;
&#xD;
          -  Participants must have an ejection fraction by echocardiogram (ECHO) or Multiple-gated&#xD;
             Acquisition Scan (MUGA) scan ≥ 45%&#xD;
&#xD;
          -  Patients must have adequate pulmonary function studies &gt; 50% of predicted on&#xD;
             mechanical aspects (Forced Expiratory Volume 1 (FEV1), Forced Vital Capacity (FVC) and&#xD;
             diffusion capacity (DLCO) &gt; 50% of predicted. If the patient is unable to complete&#xD;
             pulmonary function tests due to MM related pain or other conditions, an exception may&#xD;
             be granted if the principal investigator documents that the patient is a candidate for&#xD;
             high dose therapy.&#xD;
&#xD;
          -  Patients must have signed an Institutional Review Board (IRB)-approved informed&#xD;
             consent indicating their understanding of the proposed treatment and that the protocol&#xD;
             has been approved by the Institutional Review Board (IRB).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No evidence of high-risk disease&#xD;
&#xD;
          -  Poorly controlled hypertension, diabetes mellitus, active or uncontrolled hepatitis,&#xD;
             or other serious medical or psychiatric illness that could potentially interfere with&#xD;
             the completion of treatment according to this protocol.&#xD;
&#xD;
          -  Patients must not have prior malignancy, except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, or other cancer for which the&#xD;
             patient has not received treatment for one year prior to enrollment. Other cancers&#xD;
             will only be acceptable if the patient's life expectancy exceeds five years.&#xD;
&#xD;
          -  Pregnant or nursing women may not participate. Women of childbearing potential must&#xD;
             have a negative pregnancy documented within one week of registration.&#xD;
&#xD;
          -  Subjects of reproductive potential may not participate unless they have agreed to use&#xD;
             an effective contraceptive method.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frits van Rhee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas for Medical Science-Myeloma Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2016</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

